Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder

OBJECTIVE: To analyze the clinical effect of tamsulosin and Solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder and its safety. Another objective was to investigate the clinical effect and safety of mega dose of tamsulosin in the treatment of benign pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hui, Chang, Yanhua, Liang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648978/
https://www.ncbi.nlm.nih.gov/pubmed/29067079
http://dx.doi.org/10.12669/pjms.334.12757
_version_ 1783272480820953088
author Wang, Hui
Chang, Yanhua
Liang, Hui
author_facet Wang, Hui
Chang, Yanhua
Liang, Hui
author_sort Wang, Hui
collection PubMed
description OBJECTIVE: To analyze the clinical effect of tamsulosin and Solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder and its safety. Another objective was to investigate the clinical effect and safety of mega dose of tamsulosin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. METHODS: One hundred and twenty-four patients who were admitted to the Dept. of Urology at Binzhou People’s Hospital, , China with confirmed benign prostatic hyperplasia (BPH) with overactive bladder were randomly divided into two groups. Sixty-two patients in the control group were treated with tamsulosin, while sixty-two patients in the observation group were treated with tamsulosin in combination with solifenacin. The treatment of both groups lasted for 12 weeks. The effect and adverse reaction were compared between the two groups. RESULTS: The international prostate symptom score (IPSS), quality of life (QOL), and overactive bladder symptom score (OABSS), Q(max), pulmonary vascular resistance (PVR), daytime urination frequency, urgent urination frequency, urge urinary incontinence frequency and night urinary frequency of both groups improved after treatment, and the difference had statistical significance (P<0.05). The differences of the observation indexes (except PVR) in the observation group before and after treatment was significantly different with those of the control group (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, but the difference had no statistical significance (X(2)=2.843, P>0.05). CONCLUSION: Treating benign prostatic hyperplasia in combination with overactive bladder with tamsulosin in combination with solifenacin is more effective than tamsulosin, without significantly increasing adverse reactions. Thus the therapy is worth clinical promotion.
format Online
Article
Text
id pubmed-5648978
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Professional Medical Publications
record_format MEDLINE/PubMed
spelling pubmed-56489782017-10-24 Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder Wang, Hui Chang, Yanhua Liang, Hui Pak J Med Sci Original Article OBJECTIVE: To analyze the clinical effect of tamsulosin and Solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder and its safety. Another objective was to investigate the clinical effect and safety of mega dose of tamsulosin in the treatment of benign prostatic hyperplasia in combination with overactive bladder. METHODS: One hundred and twenty-four patients who were admitted to the Dept. of Urology at Binzhou People’s Hospital, , China with confirmed benign prostatic hyperplasia (BPH) with overactive bladder were randomly divided into two groups. Sixty-two patients in the control group were treated with tamsulosin, while sixty-two patients in the observation group were treated with tamsulosin in combination with solifenacin. The treatment of both groups lasted for 12 weeks. The effect and adverse reaction were compared between the two groups. RESULTS: The international prostate symptom score (IPSS), quality of life (QOL), and overactive bladder symptom score (OABSS), Q(max), pulmonary vascular resistance (PVR), daytime urination frequency, urgent urination frequency, urge urinary incontinence frequency and night urinary frequency of both groups improved after treatment, and the difference had statistical significance (P<0.05). The differences of the observation indexes (except PVR) in the observation group before and after treatment was significantly different with those of the control group (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, but the difference had no statistical significance (X(2)=2.843, P>0.05). CONCLUSION: Treating benign prostatic hyperplasia in combination with overactive bladder with tamsulosin in combination with solifenacin is more effective than tamsulosin, without significantly increasing adverse reactions. Thus the therapy is worth clinical promotion. Professional Medical Publications 2017 /pmc/articles/PMC5648978/ /pubmed/29067079 http://dx.doi.org/10.12669/pjms.334.12757 Text en Copyright: © Pakistan Journal of Medical Sciences http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Wang, Hui
Chang, Yanhua
Liang, Hui
Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder
title Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder
title_full Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder
title_fullStr Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder
title_full_unstemmed Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder
title_short Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder
title_sort tamsulosin and solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648978/
https://www.ncbi.nlm.nih.gov/pubmed/29067079
http://dx.doi.org/10.12669/pjms.334.12757
work_keys_str_mv AT wanghui tamsulosinandsolifenacininthetreatmentofbenignprostatichyperplasiaincombinationwithoveractivebladder
AT changyanhua tamsulosinandsolifenacininthetreatmentofbenignprostatichyperplasiaincombinationwithoveractivebladder
AT lianghui tamsulosinandsolifenacininthetreatmentofbenignprostatichyperplasiaincombinationwithoveractivebladder